Lenvima 8 mg (Lenvatinib (Lenvatinib Mesylate) CAPSULE) 8 MG

Lenvima 8 mg is a multi-targeted tyrosine kinase inhibitor designed to treat various forms of advanced cancer. It works by blocking multiple signaling pathways responsible for tumor growth, angiogenesis, and cancer cell survival.

• Differentiated thyroid cancer: Used to treat differentiated thyroid cancer that is no longer responding to radioactive iodine treatment.
• Hepatocellular carcinoma: Used as a first-line treatment for unresectable hepatocellular carcinoma.
• Renal cell carcinoma: Used in combination with everolimus for advanced renal cell carcinoma following prior anti-angiogenic therapy.
• Endometrial carcinoma: Used in combination with pembrolizumab for advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

• Lenvatinib works by inhibiting multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. By blocking these kinases, Lenvima 8 mg stops the formation of new blood vessels, cuts off the blood supply to cancer cells, and reduces their growth.

Lenvima 8 mg may cause various side effects, ranging from common to serious. Common Side Effects:

• Fatigue
• Diarrhea
• Decreased appetite
• Nausea
• Vomiting
• Hypertension
• Protein in the urine
• Weight loss
• Stomach pain
• Headache

Serious or Rare Side Effects

• Severe high blood pressure
• Heart problems
• Liver problems
• Kidney problems
• Bleeding
• Blood clots
• Hole in the stomach or intestines
• Thyroid problems
• Reversible posterior leukoencephalopathy syndrome (RPLS)
• Severe skin reactions

Lenvima 8 mg should be used with caution and under the supervision of a healthcare professional. It is important to follow the prescribed dosage and monitor for any adverse effects. Precautions include:

• Blood pressure monitoring: Regularly monitor blood pressure as Lenvima can cause hypertension.
• Heart function monitoring: Assess heart function before and during treatment.
• Liver function monitoring: Regularly monitor liver function tests.
• Kidney function monitoring: Regularly monitor kidney function tests.
• Thyroid function monitoring: Regularly monitor thyroid function tests.
• Pregnancy: Lenvima should not be used during pregnancy as it can harm the fetus.
• Store at room temperature: Keep the medication in its original container, protect it from light and moisture, and keep it out of the reach of children.

Lenvima 8 mg may interact with other medications, which can affect its efficacy or increase the risk of side effects. Major Interactions (Avoid):

• Strong CYP3A4 inducers: Avoid concomitant use as they can decrease the concentration of Lenvatinib.
• Strong CYP3A4 inhibitors: Avoid concomitant use as they can increase the concentration of Lenvatinib.
• Moderate Interactions (Monitor Closely):
• Antihypertensive drugs: Monitor blood pressure closely as Lenvima can cause hypertension.
• Anticoagulants: Monitor for signs of bleeding as Lenvima can increase the risk of bleeding.
• Drugs metabolized by CYP3A4: Monitor for increased or decreased effects as Lenvatinib can affect the metabolism of these drugs.